Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Intravenous FDY-5301 for the Prevention and Treatment of ICU Acquired Weakness in Major Trauma Patients

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Intravenous FDY-5301 for the Prevention and Treatment of ICU Acquired Weakness in Major Trauma Patients

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FDY 5301 (Primary)
  • Indications Muscle weakness
  • Focus Therapeutic Use
  • Acronyms Iocyte ICU
  • Sponsors Faraday Pharmaceuticals

Most Recent Events

  • 07 Apr 2022 Status changed from active, no longer recruiting to discontinued because of difficulty identifying patients that met the inclusion criteria, as well as logistical difficulties in opening clinical ICU study sites.
  • 01 Mar 2022 Planned End Date changed from 30 Sep 2023 to 6 Mar 2022.
  • 01 Mar 2022 Planned primary completion date changed from 30 Apr 2023 to 6 Mar 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top